European best practice guidelines 17-18: adverse effects.
Hörl
W H
WH
Jacobs
C
C
Macdougall
I C
IC
Valderrábano
F
F
Parrondo
I
I
Carveth
B G
BG
Thompson
K
K
D000740:Anemia / Q000097:blood / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000150:complications / Q000401:mortality; D002408:Catheters, Indwelling / Q000009:adverse effects; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use; D005060:Europe; D006306:Health Surveys; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000401:mortality; D017410:Practice Guidelines as Topic; D016019:Survival Analysis; D013927:Thrombosis / Q000209:etiology
D006454:Hemoglobins; D004921:Erythropoietin